Diabetology & Metabolic Syndrome is a premier open-access journal published by BMC, dedicated to advancing the field of endocrinology, diabetes, and metabolic syndrome. Since its inception in 2009, the journal has established itself as a leading platform for original research, reviews, and clinical studies, offering comprehensive insights into the complexities of metabolic diseases. With an impressive ranking in the 2023 category quartiles as Q1 in both Endocrinology, Diabetes and Metabolism, and Internal Medicine, it stands among the top-tier journals in its field. Researchers will appreciate its strong emphasis on disseminating critical findings that influence clinical practices and public health policies. Accessible to a global audience, Diabetology & Metabolic Syndrome's commitment to open access enables the distribution of high-quality research without barriers, fostering an inclusive environment for knowledge sharing. With a strategic focus on the intersection of diabetes management and metabolic disorders, this journal is essential for professionals seeking to stay abreast of the latest developments and contribute to a vital area of healthcare.

Cardiovascular Diabetology is a prestigious open-access journal published by BMC, focusing on the intersecting fields of cardiology, endocrinology, diabetes, and internal medicine. Since its inception in 2002, this journal has established itself as a vital resource for researchers, clinicians, and academics dedicated to advancing knowledge in these areas. With an impressive impact factor reflected in its Q1 rankings for the year 2023 across its respective categories, including a ranking of 22nd in Cardiology and Cardiovascular Medicine and notably 15th in Internal Medicine, it positions itself at the forefront of scholarly communication. The journal encourages the dissemination and sharing of groundbreaking research, providing open access to foster engagement and collaboration among professionals globally. As it converges from 2002 to 2024, Cardiovascular Diabetology continues to be a pivotal platform for innovative studies, reviews, and critical insights that significantly impact clinical practices and medical education in the evolving landscape of cardiovascular health and diabetes management.

CURRENT DIABETES REVIEWS is a leading academic journal published by Bentham Science Publishers Ltd, dedicated to disseminating high-quality reviews and cutting-edge insights in the field of Endocrinology, Diabetes and Metabolism. Established in 1996 and actively publishing from 2005 to 2024, this journal holds a prestigious position within the academic community, evidenced by its Q2 ranking in both relevant categories for 2023 and its impactful presence in Scopus, where it ranks #83 out of 244 in Endocrinology and Diabetes and Metabolism. Despite being a subscription-based journal, it provides researchers, healthcare professionals, and students with valuable contributions that significantly advance the understanding of diabetes and related metabolic disorders. With a commitment to promoting interdisciplinary collaboration and innovation, CURRENT DIABETES REVIEWS serves as an essential resource for those seeking to stay abreast of the latest developments in diabetes research and therapies.

DIABETOLOGIA is a leading journal in the field of endocrinology and diabetes research, published by Springer since its inception in 1965. With an impactful presence in both Internal Medicine and Endocrinology, Diabetes and Metabolism, it is recognized in the Q1 quartile rankings for 2023, underscoring its significance and contribution to these disciplines. The journal holds impressive Scopus rankings, placing it in the top 5% of journals in its categories, making it an essential resource for researchers, healthcare professionals, and students dedicated to advancing knowledge and practices in diabetes care and management. DIABETOLOGIA publishes a range of peer-reviewed articles, original research, and reviews that address the latest scientific developments, clinical practices, and therapeutic innovations, contributing to the global discourse on diabetes and its related health implications. Although it does not offer Open Access options, its rigorous selection process guarantees the quality and relevance of the content, solidifying its position as a reliable reference for contemporary research. For those looking to stay at the forefront of diabetes science, DIABETOLOGIA is a vital communique in the ever-evolving landscape of medical research.

DIABETES, published by the American Diabetes Association, is a premier journal in the field of endocrinology, diabetes, and metabolism, renowned for its rigorous peer-reviewed research since its inception in 1952. With an impressive impact factor and classified in the Q1 category for both Endocrinology, Diabetes and Metabolism and Internal Medicine as of 2023, it holds a prestigious position within the scholarly community, ranked 17th out of 244 in its specialization. The journal's objective is to disseminate cutting-edge research and advance scientific understanding to ultimately improve diabetes patient care and management. While it does not offer open access options, the journal remains a vital resource for researchers, professionals, and students involved in diabetes-related studies. The ongoing dedication to excellence by the authors, reviewers, and editors ensures that DIABETES continues to be a pivotal platform for innovation and knowledge in the fight against diabetes.

JOURNAL OF DIABETES AND ITS COMPLICATIONS is a distinguished peer-reviewed journal published by Elsevier Science Inc, dedicated to advancing the knowledge and management of diabetes and its multifaceted complications. With an ISSN of 1056-8727 and E-ISSN 1873-460X, this journal has established its significance in the fields of Endocrinology, Diabetes and Metabolism, and Internal Medicine, as reflected in its Q2 and Q1 quartile rankings for 2023, and its commendable Scopus rankings. The journal, which has been converging knowledge since 1992 and continues to publish vital research until 2024, serves as a platform for researchers, professionals, and students aiming to delve deeper into the mechanisms, treatment, and implications of diabetes and its related disorders. While access is not open, the journal remains a critical resource for those invested in understanding and combating the challenges posed by diabetes, ultimately contributing to better health outcomes.

DIABETES & METABOLISM, published by MASSON EDITEUR in France, is a leading academic journal dedicated to the fields of endocrinology, diabetes, and metabolism. With an impressive Impact Factor reflecting its esteemed reputation, the journal has been ranked in the Q1 category across multiple disciplines including Endocrinology, Internal Medicine, and more, showcasing its significance and influence in the scientific community. Since its inception in 1996 and continuing its contributions through 2024, DIABETES & METABOLISM systematically disseminates high-quality research findings, reviews, and clinical studies aimed at furthering knowledge and encouraging innovation in metabolic diseases. Although not an open-access journal, it ensures that valuable research is accessible to a broad audience through institutional subscriptions and affiliations. As a key resource for researchers, clinicians, and students alike, this journal stands at the forefront of advancing understanding and treatment options in diabetes and related metabolic disorders, making it an essential addition to any academic library.

Current Diabetes Reports is a leading academic journal published by CURRENT MEDICINE GROUP, dedicated to advancing research and clinical practices in the field of diabetes and endocrinology. With an impressive impact factor and ranked in the prestigious Q1 category for both Endocrinology, Diabetes and Metabolism and Internal Medicine, this journal serves as a vital resource for researchers, clinicians, and students alike. Established in 2001 and converging years up to 2024, Current Diabetes Reports aims to disseminate high-quality, peer-reviewed research articles, reviews, and clinical studies that address the multifaceted challenges of diabetes management and treatment. As it continues to thrive within a robust international community, the journal provides critical insights that are essential for improving patient outcomes and informing public health policies in the United States and beyond.

Clinical Obesity, published by WILEY, is a leading journal in the field of Endocrinology, Diabetes, and Metabolism that strives to advance the understanding of obesity-related health issues. With an ISSN of 1758-8103 and an E-ISSN of 1758-8111, this journal provides a platform for cutting-edge research and findings pertaining to the epidemiology, pathophysiology, prevention, and treatment of obesity. Recognized with a Q2 ranking in both Endocrinology, Diabetes and Metabolism and Medicine (miscellaneous) categories, and boasting a Scopus rank of #90 out of 244, Clinical Obesity encompasses innovative studies that influence clinical practice and public health policies. While this journal operates under a subscription model, its discipline-specific contributions are invaluable for researchers, healthcare professionals, and students keen on addressing the complexities of obesity in a comprehensive manner.

Diabetologie und Stoffwechsel is a prominent academic journal specializing in the fields of endocrinology, diabetes, and metabolism, published by GEORG THIEME VERLAG KG. Since its inception in 2006, this German journal has strived to disseminate cutting-edge research and innovative findings that advance the understanding of metabolic disorders and the management of diabetes. With an ISSN of 1861-9002 and an E-ISSN of 1861-9010, it caters to a diverse audience ranging from researchers to healthcare professionals and students in the medical field. While it currently holds a Q4 ranking in the 2023 Scopus quartiles for its area, the journal serves as a critical platform for emerging insights and discussions impacting diabetes care and research, fostering collaboration and knowledge-sharing in a rapidly evolving landscape. The convergence of its coverage until 2024 signifies a commitment to ongoing exploration into the complexities of metabolic health, making it a valuable resource for anyone passionate about these vital areas of health.